Dosage Forms

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.

Subunit Vaccines and the Fight Against COVID-19

CMOs and CDMOs adjust business processes as demand for COVID-19 treatments and non-pandemic related therapies puts pressure on the bio/pharma industry.

Balancing Pressing Priorities

Vaccines define the path to putting the pandemic in the rear-view mirror.

Avoiding Delays on the Road to Normalcy

Reports of myocarditis and pericarditis following Pfizer-BioNTech and Moderna vaccinations prompts warnings.

FDA Adds Warning to mRNA Vaccine Fact Sheets

The European Commission has purchased an additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022.

EC Orders 150 Million Additional Doses of Moderna’s COVID-19 Vaccine

EMA's recent positive opinion for a recombinant vaccine for rabbits developed using Algenex’s proprietary and patent protected Baculovirus vector-mediated expression platform, CrisBio, should push the full commercialization of the platform forward.

EMA Issues Positive Opinion for CrisBio Developed Vaccine, Validating the Platform

CureVac’s first-generation COVID-19 vaccine candidate, CvnCoV, did not meet efficacy targets in a second interim analysis. 

CureVac Releases Interim Results from COVID-19 Vaccine Candidate Trial

Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.

PHE Analysis Demonstrates Efficacy of COVID Vaccines Against Delta Variant

Sanofi’s new Pennsylvania facility expands production of Fluzone High-Dose Quadrivalent flu vaccine.

Sanofi Facility for Flu Vaccine Licensed by FDA

Novavax’s COVID-19 vaccine is 90.4% effective and maintains efficacy when administered with an influenza vaccine.